# Entrada Therapeutics Reports Positive Early Data for ENTR-601-45

- URL: https://stocks.freetheai.org/news/entrada-therapeutics-reports-positive-early-data-for-entr-601-45-cd0f53
- Published: 2026-10-14T11:53:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NASDAQ:TRDA](https://stocks.freetheai.org/symbols/NASDAQ-TRDA)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Entrada Therapeutics (TRDA) reported favorable safety and preliminary efficacy results from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study evaluating ENTR-601-45. In the initial trial group receiving 5 mg/kg intravenous doses, the treatment met its primary objectives for safety and tolerability. Despite the clinical results, shares of the company declined 11.64% to 4.86 USD.

The double-blind study showed that treated participants experienced a 0.10% mean increase in dystrophin levels compared to a 0.02% mean decrease in the placebo group after three doses. Treated participants also demonstrated a 0.15% mean increase in exon skipping compared to a 0.04% decrease for placebo. Laboratory evaluations showed no renal safety signals or hypomagnesemia, with eGFR, cystatin C, and magnesium levels staying within normal ranges.

Dosing is currently underway for Cohort 2 at a dose of 10 mg/kg. The company remains on track to report topline data for Cohort 2 in the first half of 2027, before advancing to Cohort 3 at doses up to 15 mg/kg.

## Key points

- Entrada Therapeutics (TRDA) met primary safety and tolerability goals in Cohort 1 of its Phase 1/2 ELEVATE-45-201 trial at 5 mg/kg.
- Treated participants achieved a 0.10% mean increase in dystrophin and a 0.15% mean increase in exon skipping after three doses.
- No hypomagnesemia or renal safety issues were observed, with eGFR, cystatin C, and magnesium levels in normal ranges.
- Cohort 2 dosing at 10 mg/kg is ongoing, with data expected in the first half of 2027 prior to starting Cohort 3.
- Entrada Therapeutics shares dropped 11.64% to 4.86 USD following the announcement.

## Questions and answers

### What were the Phase 1/2 trial results for Entrada Therapeutics candidate ENTR-601-45?

Cohort 1 met primary safety and tolerability goals at 5 mg/kg. Treated participants achieved a 0.10% mean increase in dystrophin and a 0.15% mean increase in exon skipping after three doses, with no kidney or magnesium safety issues.

### When will Entrada Therapeutics report Cohort 2 trial data?

The company is on track to report topline data for Cohort 2 in the first half of 2027, followed by Cohort 3 dosing up to 15 mg/kg.

### How did Entrada Therapeutics stock move after the trial results?

Entrada Therapeutics (TRDA) shares fell 11.64% to 4.86 USD following the Phase 1/2 data release.